Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 8 | 2025 | 1198 | 3.620 |
Why?
|
| Receptor, ErbB-2 | 2 | 2024 | 56 | 1.760 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 130 | 1.060 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2025 | 12 | 0.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 449 | 0.860 |
Why?
|
| Breast Neoplasms, Male | 1 | 2024 | 14 | 0.850 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 128 | 0.850 |
Why?
|
| Immunoconjugates | 1 | 2023 | 90 | 0.810 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 67 | 0.780 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 14 | 0.780 |
Why?
|
| Febrile Neutropenia | 1 | 2021 | 6 | 0.710 |
Why?
|
| Frail Elderly | 1 | 2021 | 109 | 0.660 |
Why?
|
| Antineoplastic Agents | 2 | 2025 | 663 | 0.630 |
Why?
|
| Capecitabine | 1 | 2019 | 13 | 0.630 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 42 | 0.620 |
Why?
|
| Frailty | 1 | 2021 | 130 | 0.600 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2019 | 66 | 0.580 |
Why?
|
| Body Mass Index | 1 | 2021 | 867 | 0.530 |
Why?
|
| Female | 11 | 2025 | 32912 | 0.460 |
Why?
|
| Hospitalization | 1 | 2021 | 1364 | 0.420 |
Why?
|
| Humans | 12 | 2025 | 63511 | 0.340 |
Why?
|
| Neoplasms | 1 | 2021 | 1364 | 0.330 |
Why?
|
| Prospective Studies | 2 | 2024 | 3301 | 0.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2024 | 35 | 0.220 |
Why?
|
| Receptors, Progesterone | 1 | 2024 | 110 | 0.220 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 200 | 0.210 |
Why?
|
| Survivorship | 1 | 2024 | 14 | 0.210 |
Why?
|
| Mastectomy | 1 | 2024 | 58 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2023 | 89 | 0.200 |
Why?
|
| India | 1 | 2023 | 159 | 0.200 |
Why?
|
| Disease Management | 1 | 2024 | 232 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 22 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 87 | 0.190 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 58 | 0.190 |
Why?
|
| Hemophilia A | 1 | 2022 | 57 | 0.190 |
Why?
|
| Treatment Outcome | 2 | 2024 | 5699 | 0.190 |
Why?
|
| Germ Cells | 1 | 2022 | 110 | 0.180 |
Why?
|
| Genetic Testing | 1 | 2022 | 134 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 455 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 31 | 0.180 |
Why?
|
| Mammography | 1 | 2024 | 281 | 0.170 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 508 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2023 | 339 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5474 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6673 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 322 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 238 | 0.160 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 25 | 0.160 |
Why?
|
| Chest Pain | 1 | 2019 | 84 | 0.150 |
Why?
|
| Algorithms | 1 | 2023 | 1003 | 0.140 |
Why?
|
| Inpatients | 1 | 2021 | 305 | 0.140 |
Why?
|
| Middle Aged | 3 | 2024 | 17644 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 762 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1094 | 0.140 |
Why?
|
| Pregnancy | 1 | 2025 | 2335 | 0.140 |
Why?
|
| Cardiac Catheterization | 1 | 2019 | 286 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 2574 | 0.110 |
Why?
|
| HIV Infections | 1 | 2022 | 970 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2578 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2021 | 2082 | 0.110 |
Why?
|
| Male | 2 | 2024 | 29927 | 0.090 |
Why?
|
| Aged | 1 | 2021 | 14472 | 0.060 |
Why?
|
| Factor VIII | 1 | 2022 | 32 | 0.050 |
Why?
|